Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 36

1.

Discovery of a Potent, Long-Acting, and CNS-Active Inhibitor (BIA 10-2474) of Fatty Acid Amide Hydrolase.

Kiss LE, Beliaev A, Ferreira HS, Rosa CP, Bonifácio MJ, Loureiro AI, Pires NM, Palma PN, Soares-da-Silva P.

ChemMedChem. 2018 Oct 22;13(20):2177-2188. doi: 10.1002/cmdc.201800393. Epub 2018 Sep 11.

2.

Effect of opicapone multiple-dose regimens on levodopa pharmacokinetics.

Rocha JF, Sicard É, Fauchoux N, Falcão A, Santos A, Loureiro AI, Pinto R, Bonifácio MJ, Nunes T, Almeida L, Soares-da-Silva P.

Br J Clin Pharmacol. 2017 Mar;83(3):540-553. doi: 10.1111/bcp.13156. Epub 2016 Dec 2.

3.

Beyond a pleural effusion: Primary pleuropulmonary sarcomas and the challenge of diagnosis.

Apolinário D, Silva J, Loureiro AI, Noya R, Carvalho L.

Rev Port Pneumol (2006). 2016 Sep-Oct;22(5):298-9. doi: 10.1016/j.rppnen.2016.03.011. Epub 2016 May 4. No abstract available.

4.

Eslicarbazepine acetate for the treatment of focal epilepsy: an update on its proposed mechanisms of action.

Soares-da-Silva P, Pires N, Bonifácio MJ, Loureiro AI, Palma N, Wright LC.

Pharmacol Res Perspect. 2015 Mar;3(2):e00124. doi: 10.1002/prp2.124. Epub 2015 Mar 30. Review.

5.

Role of P-glycoprotein and permeability upon the brain distribution and pharmacodynamics of etamicastat: a comparison with nepicastat.

Loureiro AI, Bonifácio MJ, Fernandes-Lopes C, Pires N, Igreja B, Wright LC, Soares-da-Silva P.

Xenobiotica. 2015;45(9):828-39. doi: 10.3109/00498254.2015.1018985. Epub 2015 Jun 10.

PMID:
25915108
6.

Distribution and pharmacokinetics of etamicastat and its N-acetylated metabolite (BIA 5-961) in dog and monkey.

Loureiro AI, Soares-da-Silva P.

Xenobiotica. 2015;45(10):903-11. doi: 10.3109/00498254.2015.1024780. Epub 2015 Apr 14.

PMID:
25869244
7.

Cardiovascular safety pharmacology profile of etamicastat, a novel peripheral selective dopamine-β-hydroxylase inhibitor.

Pires NM, Loureiro AI, Igreja B, Lacroix P, Soares-da-Silva P.

Eur J Pharmacol. 2015 Mar 5;750:98-107. doi: 10.1016/j.ejphar.2015.01.035. Epub 2015 Jan 30.

PMID:
25641747
8.

Effects of eslicarbazepine acetate on acute and chronic latrunculin A-induced seizures and extracellular amino acid levels in the mouse hippocampus.

Sierra-Paredes G, Loureiro AI, Wright LC, Sierra-Marcuño G, Soares-da-Silva P.

BMC Neurosci. 2014 Dec 20;15:134. doi: 10.1186/s12868-014-0134-2.

9.

Pharmacological profile of opicapone, a third-generation nitrocatechol catechol-O-methyl transferase inhibitor, in the rat.

Bonifácio MJ, Torrão L, Loureiro AI, Palma PN, Wright LC, Soares-da-Silva P.

Br J Pharmacol. 2015 Apr;172(7):1739-52. doi: 10.1111/bph.13020. Epub 2015 Jan 20.

10.

Blood pressure-decreasing effect of etamicastat alone and in combination with antihypertensive drugs in the spontaneously hypertensive rat.

Igreja B, Pires NM, Bonifácio MJ, Loureiro AI, Fernandes-Lopes C, Wright LC, Soares-da-Silva P.

Hypertens Res. 2015 Jan;38(1):30-8. doi: 10.1038/hr.2014.143. Epub 2014 Oct 9.

PMID:
25298210
11.

Eslicarbazepine and the enhancement of slow inactivation of voltage-gated sodium channels: a comparison with carbamazepine, oxcarbazepine and lacosamide.

Hebeisen S, Pires N, Loureiro AI, Bonifácio MJ, Palma N, Whyment A, Spanswick D, Soares-da-Silva P.

Neuropharmacology. 2015 Feb;89:122-35. doi: 10.1016/j.neuropharm.2014.09.008. Epub 2014 Sep 19.

PMID:
25242737
12.

Etamicastat, a new dopamine-ß-hydroxylase inhibitor, pharmacodynamics and metabolism in rat.

Loureiro AI, Bonifácio MJ, Fernandes-Lopes C, Igreja B, Wright LC, Soares-da-Silva P.

Eur J Pharmacol. 2014 Oct 5;740:285-94. doi: 10.1016/j.ejphar.2014.07.027. Epub 2014 Jul 21.

PMID:
25058908
13.

Human disposition, metabolism and excretion of etamicastat, a reversible, peripherally selective dopamine β-hydroxylase inhibitor.

Loureiro AI, Rocha JF, Fernandes-Lopes C, Nunes T, Wright LC, Almeida L, Soares-da-Silva P.

Br J Clin Pharmacol. 2014 Jun;77(6):1017-26. doi: 10.1111/bcp.12274.

14.

N-acetylation of etamicastat, a reversible dopamine-β-hydroxylase inhibitor.

Loureiro AI, Fernandes-Lopes C, Bonifácio MJ, Wright LC, Soares-da-Silva P.

Drug Metab Dispos. 2013 Dec;41(12):2081-6. doi: 10.1124/dmd.113.053736. Epub 2013 Sep 6.

PMID:
24013186
15.

Opicapone: a short lived and very long acting novel catechol-O-methyltransferase inhibitor following multiple dose administration in healthy subjects.

Rocha JF, Almeida L, Falcão A, Palma PN, Loureiro AI, Pinto R, Bonifácio MJ, Wright LC, Nunes T, Soares-da-Silva P.

Br J Clin Pharmacol. 2013 Nov;76(5):763-75. doi: 10.1111/bcp.12081.

16.

Pharmacokinetics, pharmacodynamics and tolerability of opicapone, a novel catechol-O-methyltransferase inhibitor, in healthy subjects: prediction of slow enzyme-inhibitor complex dissociation of a short-living and very long-acting inhibitor.

Almeida L, Rocha JF, Falcão A, Palma PN, Loureiro AI, Pinto R, Bonifácio MJ, Wright LC, Nunes T, Soares-da-Silva P.

Clin Pharmacokinet. 2013 Feb;52(2):139-51. doi: 10.1007/s40262-012-0024-7.

PMID:
23248072
17.

Involvement of pharmacies in tuberculosis treatment.

Antunes A, Gomes J, Belchior I, Loureiro AI, Carvalho A, Madeira A, Duarte R.

Eur Respir J. 2012 Dec;40(6):1581-2. doi: 10.1183/09031936.00005012. No abstract available.

18.

Computation of the binding affinities of catechol-O-methyltransferase inhibitors: multisubstate relative free energy calculations.

Palma PN, Bonifácio MJ, Loureiro AI, Soares-da-Silva P.

J Comput Chem. 2012 Apr 5;33(9):970-86. doi: 10.1002/jcc.22926. Epub 2012 Jan 25.

PMID:
22278964
19.

[Ulcerated lesion of the cecum as a form of presentation of gastrointestinal tuberculosis].

Loureiro AI, Pinto CS, Oliveira AI, Calvário F, Carvalho A, Duarte R.

Acta Med Port. 2011 Mar-Apr;24(2):371-4. Epub 2011 May 20. Portuguese.

20.

Development and validation of an enantioselective liquid-chromatography/tandem mass spectrometry method for the separation and quantification of eslicarbazepine acetate, eslicarbazepine, R-licarbazepine and oxcarbazepine in human plasma.

Loureiro AI, Fernandes-Lopes C, Wright LC, Soares-da-Silva P.

J Chromatogr B Analyt Technol Biomed Life Sci. 2011 Sep 1;879(25):2611-8. doi: 10.1016/j.jchromb.2011.07.019. Epub 2011 Jul 20.

PMID:
21816689
21.

Hepatic UDP-glucuronosyltransferase is responsible for eslicarbazepine glucuronidation.

Loureiro AI, Fernandes-Lopes C, Bonifácio MJ, Wright LC, Soares-da-Silva P.

Drug Metab Dispos. 2011 Sep;39(9):1486-94. doi: 10.1124/dmd.111.038620. Epub 2011 Jun 14.

PMID:
21673130
22.

Single-dose tolerability, pharmacokinetics, and pharmacodynamics of etamicastat (BIA 5-453), a new dopamine β-hydroxylase inhibitor, in healthy subjects.

Rocha JF, Vaz-Da-Silva M, Nunes T, Igreja B, Loureiro AI, Bonifácio MJ, Wright LC, Falcão A, Almeida L, Soares-Da-Silva P.

J Clin Pharmacol. 2012 Feb;52(2):156-70. doi: 10.1177/0091270010390805.

PMID:
21343348
23.

Pharmacokinetics, disposition, and metabolism of [14C]-nebicapone in humans.

Wright LC, Maia J, Loureiro AI, Almeida L, Soares-Da-Silva P.

Drug Metab Lett. 2010 Aug;4(3):149-62.

PMID:
20642448
24.

Chronopharmacology of nebicapone, a new catechol-O-methyltransferase inhibitor.

Almeida L, Loureiro AI, Vaz-da-Silva M, Torrão L, Maia J, Fernandes-Lopes C, Falcão A, Igreja B, Wright L, Soares-da-Silva P.

Curr Med Res Opin. 2010 May;26(5):1097-108. doi: 10.1185/03007991003694472.

PMID:
20225994
25.

Pharmacokinetic-pharmacodynamic interaction between nebicapone and controlled-release levodopa/benserazide: a single-center, Phase I, double-blind, randomized, placebo-controlled, four-way crossover study in healthy subjects.

Nunes T, Machado R, Rocha JF, Fernandes-Lopes C, Costa R, Torrão L, Loureiro AI, Falcão A, Vaz-da-Silva M, Wright L, Almeida L, Soares-da-Silva P.

Clin Ther. 2009 Oct;31(10):2258-71. doi: 10.1016/j.clinthera.2009.10.019.

PMID:
19922897
26.

Pharmacokinetics of trans-resveratrol following repeated administration in healthy elderly and young subjects.

Nunes T, Almeida L, Rocha JF, Falcão A, Fernandes-Lopes C, Loureiro AI, Wright L, Vaz-da-Silva M, Soares-da-Silva P.

J Clin Pharmacol. 2009 Dec;49(12):1477-82. doi: 10.1177/0091270009339191. Epub 2009 Oct 1. No abstract available.

PMID:
19797536
27.

Species differences in pharmacokinetic and pharmacodynamic properties of nebicapone.

Bonifácio MJ, Loureiro AI, Torrão L, Fernandes-Lopes C, Wright L, Pinho MJ, Soares-da-Silva P.

Biochem Pharmacol. 2009 Oct 15;78(8):1043-51. doi: 10.1016/j.bcp.2009.05.036. Epub 2009 Jun 6.

PMID:
19505437
28.

Pharmacokinetic and safety profile of trans-resveratrol in a rising multiple-dose study in healthy volunteers.

Almeida L, Vaz-da-Silva M, Falcão A, Soares E, Costa R, Loureiro AI, Fernandes-Lopes C, Rocha JF, Nunes T, Wright L, Soares-da-Silva P.

Mol Nutr Food Res. 2009 May;53 Suppl 1:S7-15. doi: 10.1002/mnfr.200800177.

PMID:
19194969
29.

Effect of food on the pharmacokinetic profile of trans-resveratrol.

Vaz-da-Silva M, Loureiro AI, Falcao A, Nunes T, Rocha JF, Fernandes-Lopes C, Soares E, Wright L, Almeida L, Soares-da-Silva P.

Int J Clin Pharmacol Ther. 2008 Nov;46(11):564-70.

PMID:
19000554
30.

Pharmacokinetic-pharmacodynamic interaction between nebicapone, a novel catechol-o-methyltransferase inhibitor, and controlled-release levodopa/carbidopa 200 mg/50 mg : randomized, double-blind, placebo-controlled, crossover study in healthy subjects.

Vaz-da-Silva M, Loureiro AI, Nunes T, Lopes C, Rocha J, Machado R, Costa R, Torrão L, Falcão A, Wright L, Almeida L, Soares-da-Silva P.

Drugs R D. 2008;9(6):435-46. doi: 10.2165/0126839-200809060-00006.

PMID:
18989992
31.

Bioavailability and bioequivalence of two enteric-coated formulations of omeprazole in fasting and fed conditions.

Vaz-da-Silva M, Loureiro AI, Nunes T, Maia J, Tavares S, Falcão A, Silveira P, Almeida L, Soares-da-Silva P.

Clin Drug Investig. 2005;25(6):391-9.

PMID:
17532679
32.

Human metabolism of nebicapone (BIA 3-202), a novel catechol-o-methyltransferase inhibitor: characterization of in vitro glucuronidation.

Loureiro AI, Bonifácio MJ, Fernandes-Lopes C, Almeida L, Wright LC, Soares-Da-Silva P.

Drug Metab Dispos. 2006 Nov;34(11):1856-62. Epub 2006 Jun 21.

PMID:
16790555
33.

Comparative study of ortho- and meta-nitrated inhibitors of catechol-O-methyltransferase: interactions with the active site and regioselectivity of O-methylation.

Palma PN, Rodrigues ML, Archer M, Bonifácio MJ, Loureiro AI, Learmonth DA, Carrondo MA, Soares-da-Silva P.

Mol Pharmacol. 2006 Jul;70(1):143-53. Epub 2006 Apr 17.

PMID:
16618795
34.

Molecular modeling and metabolic studies of the interaction of catechol-O-methyltransferase and a new nitrocatechol inhibitor.

Palma PN, Bonifácio MJ, Loureiro AI, Wright LC, Learmonth DA, Soares-da-Silva P.

Drug Metab Dispos. 2003 Mar;31(3):250-8.

PMID:
12584150
35.

Metabolism of 10,11-dihydro-10-hydroxyimino-5H-dibenz/b, f/azepine-5-carboxamide, a potent anti-epileptic drug.

Hainzl D, Loureiro AI, Parada A, Soares-da-silva P.

Xenobiotica. 2002 Feb;32(2):131-40.

PMID:
11868969
36.

BIA 3-202, a novel catechol-O-methyltransferase inhibitor, enhances the availability of L-DOPA to the brain and reduces its O-methylation.

Parada A, Loureiro AI, Vieira-Coelho MA, Hainzl D, Soares-da-Silva P.

Eur J Pharmacol. 2001 May 18;420(1):27-32.

PMID:
11412836

Supplemental Content

Loading ...
Support Center